111
Практическая онкология. - 2003. - № 4. - С. 3-6.
117. Хвастунов, Р. А. Комплексная диагностика рецидивов рака яичников / Р.А. Хвастунов, Т.Ф. Девятченко, В.В. Столяренко // Материалы VI
Всероссийского съезда онкологов. – Mосква, 2005. – Т. I. – С. 213-214.
118.Шалашная, Е.В. Исследование влияния химиопрепаратов на уровень эндогенной интоксикации, интенсивность свободорадикального окисления и мембранный аппарат клеток крови больных с рецидивами рака шейки матки в опытах in vitro / Е.В. Шалашная, И.А. Горошинская, Г.А. Неродко, Е.А. Гуськова
//Сибирский онкологический журнал. - 2008. - №2. - С. 50-54.
119.Шевченко, А.В. Полиморфизм промоторного региона генов IL-4, IL-6 и
IL-10 у пациенток с раком молочной железы / А.В. Шевченко, О.В. Голованова, М.Ю. Коломейчук, В.И. Коненков // Медицинская иммунология. – 2009. – Т. 11,
№1. – С. 21-28.
120.Яйцев, С.В. Преимущества лапароскопии как современного метода выполнения радикальных операций при раке тела матки и яичников / С.В. Яйцев, Р. И. Асабаева // Медицинская наука и образование Урала. -2014. – Т. 15, № 3(79).
– С 117-120.
121.Якушенко, Е.В. Получение рекомбинантного интерлейкина-18 и изучение его противоопухолевой активности / Е.В. Якушенко, Ю.А. Лопатникова, Е.А. Храпов и др. // Бюллетень СО РАМН. – 2007. – № 2 (124). – C. 23-26.
122.Abola, M.V. Association between treatment toxicity and outcomes in oncology clinical trials / M.V. Abola, V. Prasad, A.B. Jena // Ann. Oncol. - 2014. - V. 25 (11). - P. 2284-2289. doi: 10.1093/annonc/mdu444. Epub 2014 Sep 5. PMID: 25193993; PMCID: PMC4207731
123.Allen, R.G. Oxidative stress and gene regulation / R.G. Allen, M. Tresini // Free. Radic. Biol. Med. – 2000. – V. 28 (3). – Р. 463–499.
124.Al-Shammaa, H.A. Current status and future strategies of cytoreductive surgery plus intraperitonealhyperthermic chemotherapy for peritoneal carcinomatosis / H.A. Al-Shammaa, Y. Yonemura // World. J. gastroenterol. – 2008. – V. 14. – P. 11591166.
Рекомендовано к изучению сайтом МедУнивер - https://meduniver.com/
112
125. Alvero, A.B. Distinct subpopulations of epithelial ovarian cancer cells can differentially induce macrophages and T regulatory cells toward a pro-tumor phenotype / A.B. Alvero, M.K. Montagna, V. Craveiro et al. // Am. J. Reprod Immunol. – 2012. –
V.67 (3). – Р. 256-265.
126.Ambrosone, C.B. Antioxid. Redox / C.B. Ambrosone // Signal. – 2000. – V. 2(4). – P. 903-917.
127.American Cancer Society. Statistics 2000 cancer facts and figures selected cancers ovary [Electronic resource]. Available from URL: http://www.cancer.org (accessed on: 16 Oct. 2000).
128.Apte, R. Opposing effects IL-la and IL-ip cytokine gene-transfer approaches / R. Apte, T. Dvorkin, E. Fima, X. Song // Eur. Cytokine. Netw. – 1998. –
V.9 (3). – P. 402.
129.Arakawa, A. Pharmacokinetic and pharmacodynamic analysis of combined chemotherapy with carboplatin and paclitaxel for patients with ovarian cancer / A. Arakawa, H. Nishikawa, K. Suzumori, N. Kato // Int. J. Clin. Oncol. – 2001. – V. 6 (5).
–P. 248-252.
130.Balkwill, F. Inflammation and cancer: Back to Virchow? / F. Balkwill, A. Mantovani // Lancet. – 2001. – V. 357 (9255). – P. 539.
131.Bartel, F. Both germ line and somatic genetics of the p53 pathway affect
ovarian cancer incidence and survival / F. Bartel, J. Jung, A. Böhnke et al. // Clin. Cancer Res. – 2008. – V. 14 (1). – P. 89.
132. Baysal, B.E. Mutation in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma / B.E. Baysal, R.E. Ferrell, J.E. Willett-Brozick // Science. – 2000. – V. 287. – P. 848–851.
133.Ben-Baruch, А. Inflammation associated immune suppresstion in cancer: the roles played by cytokines, chemokines and adelitional mediators / А. Ben-Baruch // Seminars in Cancer Biology. – 2006. – V. 16 (1). – P. 38-52.
134.Bowtell, D.D. Rethinking ovarian cancer: reducing mortality from highgrade serous ovarian cancer / D.D. Bowtell, S. Bohm, A. Ahmed, P.J. Aspuria // Nat. Rev. Cancer. – 2015. – V. 15. – P. 668-679.
113
135.Brieger, K. Reactive oxygen species: from health to disease / K. Brieger, S. Schiavone, F.J.Jr. Miller, K.H. Krause // Swiss. Med. Wkly. - 2012. 142:w13659. doi: 10.4414/smw.2012.13659. PMID: 22903797
136.Brower, V. Researchers Attempting To Define Role of cytokines in Cancer Risk / V. Brower // J. of the National. Cancer. Institute. – 2005. – V. 97 (16). – P. 11751177.
137.Burger, C.W. Risk of cancer in offspring of women who underwent in vitro fertilization / C.W. Burger, J. De Kraker, F.E. Van Leeuwen // Gynecol. Oncol. – 2002.
–V. 84. – P. 525.
138.Burton, G.W. Vitamin E: molecular and biological function / G.W. Burton // Proc. Nutr. Soc. - 1999. -V. 53 (2). - P. 251-261.
139.Cannistra, S.A. Cancer of the Ovary / S.A. Cannistra // NEJM. - 2004. - V. 351. - P. 2519-2529.
140.Catheleine, M.G. Stopping ovarian cancer screening in BRCA1/2 mutation carriers: Effects on risk management decisions & outcome of risk-reducing salpingo- oopho-rectomy specimens / M.G. Catheleine, C.M. van Driel, G.H. de Bock et al. // Maturitas. – 2015. - V. 80. - P. 318-322.
141.Сerutti, P.A. Inflammation and oxidative stress in carcinogenesis / P.A. Cerutti, B.F. Trump// Cancer. Cell. - 2001. – V. 3. - P. 1-7.
142.Chan, W.Y. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers / W.Y. Chan, K.K. Cheung, J.O. Schorge et al. // Am. J. Pathol. – 2000. – V. 156 (2). – P. 409-417.
143.Choi, M. Conditional survival in ovarian cancer / M. Choi, C.D. Fuller, C.R. Jr. Thomas, S.J. Wang // Gynecol. Oncol. - 2008. - V. 109. - P. 203-209.
144.Chua, T.C. Intraoperative hperthermicintraperitoneal Chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results / T.C. Chua, G. Robertson, W. Liauw et al. // J. cancer res. clin. oncol. –
2009. – V. 135. – P. 1637-1645.
145. Comen, E. Breast cancer tumor size, nodal status, and prognosis: biology trumps anatomy / E. Comen, L. Norton, J. Massague // J. Clin. Oncol. – 2011. – V. 29
Рекомендовано к изучению сайтом МедУнивер - https://meduniver.com/
114
(19). – P. 2610-2612.
146. Choi, M. Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001 / M. Choi, C. D. Fuller, C.R. Thomas, S.J. Wang // Gynecol Oncol. – 2008. – V. 109 (2). – P. 203-209.
147.Coussens, L. M. Inflammation and cancer / L.M. Coussens, Z. Werb // Nature. – 2002. – V. 420 (6917). – P. 860-867.
148.Dobrzanski, M.J. Immunotherapy with IL-10- and IFN-γ-producing CD4
effector cells modulate «Natural» and «Inducible» CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer / M.J. Dobrzanski, K.A. Rewers-Felkins, K.A. Samad et al. // Cancer. Immunol Immunother. – 2012. – V. 61 (6).
–Р. 839-854.
149.Di Carlo, E. Neutrophils in the antitumoral immuneresponse / E. Di Carlo, Y. Formi, H. Musiani // Cheminal. Immunology and Allegry. – 2003. – V. 83. – P. 182203.
150.Edwardson, D.W. Chemotherapy and Inflammatory Cytokine Signalling in Cancer Cells and the Tumour Microenvironment / D.W. Edwardson, A.M. Parissenti, A.T. Kovala // Adv. Exp. Med. Biol. – 2019. – V. 1152. – P. 173-215.
151.Eggermont, A.M. TNF registered in Europe: does TNF get a second chance? / A.M. Eggermont // J. Immunother. – 2000. – V. 23 (4). – P. 505.
152.Egmond, M.V. Enhancement of polymorphonuclear cell mediated tumor cell killing on simultaneous engagement of FcγRI (CD64) and FcαRI (CD89) / M. Van Egmond, A.B.V. Spriel, H. Vermeulen,G. Huls // Cancer Res. – 2001. – V. 61 (40). – P. 55-60.
153.Ellis, R.E. Cytokines in ascites fluid from ovarian carcinoma / R.E. Ellis, Y. Yuan, H.R. Horvitz // Cancer Lett. – 2002. – V. 61. – P. 243-253.
154.Eltabbakh, J.L. P53 overexpression is not an in-dependent prognostic factor for patients with primary ovarian epithelial cancer / G. Eltabbakh, J.L. Belinson, A.W. Kennedy et al. // Cancer. – 1999. – V. 81. – P. 733-740.
155.Engelmann, J. How can tumor cells escape intercellular induction of apoptosis? / J. Engelmann, G. Bauer // Anticancer Res. – 2000. – V. 20 (4). – P. 2293-
115
2306.
156.Ferlay, J. Global Cancer Observatory: Cancer Today / Ferlay J., M. Ervik, F. Lam et al. - Lyon, France: International Agency for Research on Cancer. – 2018. - Available from: https://gco.iarc.fr/today, accessed 20.05.2020)
157.Gao, Y. Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: a retrospective study / Y. Gao, L. Chen, G. Cai et al. // Oncoimmunology. - 2020. - V. 9 (1). - P. 1760067. doi: 10.1080/2162402X.2020.1760067. PMID: 32391193; PMCID: PMC7199814
158.Gagnon, A. Discovery and application of protein biomarkers for ovarian cancer / A. Gagnon, B. Ye // Cerr. Opin. Obstet. Gynecol. – 2008. – V. 20. – P. 9-13.
159.Gening, T.P. Use of atomic forse microscopy for assessing paraneoplastic changes in red blood cells in carcinogenesis dynamics / T.P. Gening, A. Yu. Fedotova, D.R. Dolgova, I.I. Antoneeva // Translational. Biomedicine. -2016. - V. 7 (43). - S. 1-7.
160.Goff, B.A. Development of an ovarian cancer symptom index: possibilities for earlier detection / B.A. Goff, L.S. Mandel, C.W. Drescher et al. // Cancer. – 2007. - V. 109. – P. 221-227.
161.Нalliwell, B. Role of free radicals in the neurodegenerative diseases:therapeutic implications for antioxidant treatment / B. Нalliwell // Drugs & Againg. – 2001. - V. 18. - P. 685-716.
162.Harris, S.R. Oxidative stress contributes to the antiproliferative effects of flavone acetic acid on endothelial cells / S.R. Harris, N.J. Panaro, U.P. Thorgeirsson // Anticancer. Res. – 2000. – V. 20 (4). – P. 2249-2254.
163.Havrilesky, L. Prognostics significance of p53 mutation and p53 overexpressionih advanced epithelial ovarian cancer: a gynecoligie oncology group study / L. Havrilesky, K.M. Darcy, H. Hamdan et al. // J. of clinicov oncology. – 2003.
–V. 21 (20). – P. 3814-3825
164.Henriksen, J.R. Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy / J.R. Henriksen, L. Nederby, F. Donskov et al. // J. Ovarian. Res. - 2020. - V. 13 (1). – P. 59.
Рекомендовано к изучению сайтом МедУнивер - https://meduniver.com/
116
165. Helfinger, V. Redox control in cancer development and progression / V.
Helfinger, K. Schröder // Mol. Aspects Med. - 2018. - V. 63. - P. 88-98.
166.Hellstrom, I. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other / I. Hellstrom, K.E. Hellstrom // Adv. Exp. Med. Biol. - 2008. - V. 622. - P. 15-21.
167.Hornsveld, M. The Hallmarks of Cancer from a Redox Perspective / M. Hornsveld, T.B. Dansen // Antioxid. Redox Signal. - 2016. – V. 25 (6). – P. 300-325.
168.Howe, H.L. Annual report to the nation on the status of cancer / H.L. Howe, P.A. Wingo, M.J. Thun et al. // Int. J. Gynecol. Cancer. – 2001. – № 93. – P. 824-842.
169.Hsu, B.E. Neutrophils: Orchestrators of the Malignant Phenotype / B.E. Hsu, Y. Shen, P.M. Siegel // Front. Immunol. - 2020. – V. 11. – P. 1778. doi: 10.3389/fimmu.2020.01778. PMID: 32849639; PMCID: PMC7433712
170.Igney, F.H. CD95L mediates tumor counterattack in vitro but induces neutrophil-independent tumor rejection in vivo / F.H. Igney, C.K. Behrens, P.H. Krammer // Hint. J. Cancer. – 2005. – V. 113 (1). – P. 78-87.
171.Jiménez-Sánchez, A. Unraveling tumor-immune heterogeneity in advanced
ovarian cancer uncovers immunogenic effect of chemotherapy / A. Jiménez-Sánchez, P.
Cybulska, K.L. Mager et al. // Nat. Genet. - 2020. – V. 52 (6). – P. 582-593.
172.Janelsins, M.C. Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research / M.C. Janelsins, K.M. Mustian, O.G. Palesh, S.G. Mohile // Supportive Care in Cancer. – 2012. – V. 20 (4). – P. 831–839.
173.Kalinina, E.V. Redox-Dependent Expression of Genes Encoding NADPH Oxidase 5 and the Key Antioxidant Enzymes during Formation of Drug Resistance of Tumor Cells to Cisplatin / E.V. Kalinina, Y.A. Andreev, A.S. Petrova et al. // Bull. Exp. Biol. Med. - 2018. – V. 165 (5). – P. 678-681.
174.Kanzaki, H. Immunological aspects of endometriosis / H. Кanzaki, T. Nakajima, T. Yoshimura // Nippon Rinsho. – 2001. – V. 59 (1). – P. 44-47.
175.Kemp, M., Noneguilibrium thermodynamics of thiol/ disulfide redox systems: A perspective on redox systems biology/ M. Kemp, Y. Go, D. P. Jones // Free.
117
Radical. Biology & Medicine. - 2008. - V. 44. - P. 921-937.
176.Kinnula, V.L. Superoxide dismutases in malignant cells and human tumors
/V.L. Kinnula, J.D. Crapo // Free. Radic. Biol. Med. - 2004. - V. 36 (6). - P. 718-744.
177.Kolomeyevskaya, N. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-a and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer / N. Kolomeyevskava, K.H. Eng, A.N. Khan et al. // Gynecol. Oncol. – 2015. – P. 352-357.
178.Kos, J. IL-ip, TNFa in sera from patients with colorectal cancer: relation to prognosis / J. Kos, T. Vizin // Clin. Cancer. Res. – 2000. – V. 6. – P. 505-511.
179.Kosenkova, O.J. The problem of quality of life. in modern medicine / O.J. Kosenkova, V.J. Makarova // Ecologiya cheloveka. – 2007. – № 11. – P. 29-31.
180.Kurman, R.J. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications / R.J. Kurman, I.M. Shih // Int. J. Gynecol. Pathol. – 2008. – V. 27 (2). – P. 151-160.
181.Kurman, R.J. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory / R.J. Kurman, I.M. Shih // Am. J. Surg. Pathol. – 2010. – V. 34 (3). – P. 433-443.
182.Ledermann, J.A. Optimal treatment for relapsing ovarian cancer / J.A. Ledermann, R.S. Kristeleit // Annals. of Oncology. - 2010. - V. 2. - P. 218-222.
183.Ledermann, J.A. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up / J.A. Ledermann, F.A. Raja, C. Fotopoulou et al. // Ann. Oncol. – 2013. - V. 24. – P. 2432.
184.Levanon, K. Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis / K. Levanon, V. Ng, H.Y. Piao et al. // Oncogene. – 2010. – V. 8. – P. 1103-1113.
185.Linnane, A. W. Cellular redox regulation and prooxidant signaling systems: a new perspective on the free radical theory of aging / A. W. Linnane, H. Eastwood // Ann. NY. Acad. Sci. - 2006. - V. 1067. - P. 47-55.
186.Locksley, R.M. The TNF and TNF receptor superfamilies: integrating
Рекомендовано к изучению сайтом МедУнивер - https://meduniver.com/
118
mammalian biology / R.M. Locksley, N. Killeen, M.J. Leonardo // Cell. – 2001. – V.
104 (4). – P. 487.
187.Lowe, K.A. An international assessment of ovarian cancer incidence and mortality / K.A. Lowe, V.M. Chia, A. Taylor et al. // Gynecol Oncol. – 2013. - V. 130.
-P. 107-114.
188.Ma, R.Q. Expression and signifi cance of tumor necrosis factor receptor
associated protein 1 in epithelial ovarian cancer / R.Q. Ma, H.Y. Cheng, X. Ye //
Beijing. Da. Xue. Xue. Bao. – 2014. – V. 46 (1). – Р. 120-124.
189. Mantovani, G. Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients / G. Mantovani, A. Macciò, S. Esu // Eur. J. Cancer.
–1997. – V. 33 (4). – P. 602-607.
190.Markman, M. Second-lint treatment of ovarian cancer / M. Markman // The Oncologist. – 2000. – V. 5. – P. 26-35.
191.Merendino, R.A. Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations / R.A. Merendino, S. Gangemi, A. Ruello et al. // Int. J. Biol. Markers. – 2001. – V. 16 (2). – P. 126-129.
192.Mitchell, D.G. ACR Appropriateness Criteria: Staging and Follow-up of Ovarian Cancer / D.G. Mitchell, M.C. Javitt, P. Glanc et al. // J. Am. Coll. Radiol. –
2013. - V.10. - P. 822-827.
193.Moore, R.G. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass / R.G. Moore, D.S. McMeekin, A.K. Brown // Gynecol. Oncol. – 2009. – V. 112(1). –P. 40-46.
194.Morgan, R.J. Ovarian Cancer, Version 1.2016, NCCN clinical practice guidelines in oncology / R.J. Morgan, D.K. Armstrong, R.D. Alvarez et al. // J. Natl. Compr. Canc. Netw. – 2016. – V. 14. – P. 1134–1163.
195.Munoz, K.A. Patters of care for women with ovarian cancer in the United States / K.A. Munoz, L.C. Harlan, E.L. Trimble // Clin. Oncol. – 1997. – V. 15. – P. 3408-3415.
196.Mustea, A. Decreased IL-1 RA concentration in ascites is associated with a
119
significant improvement in overall survival in ovarian cancer / A. Mustea, C. Pirvulescu,
D.Konsgen et al. // Cytokine. – 2008. – V. 42 (1). – P. 77-84.
197.Nakanishi, K. Interleukin-18 is a unique cytokine that stimulates both Thl and Th2 responses depending on its cytokine milieu / K. Nakanishi, T. Yoshimoto, H. Tsutsu, H. Okamura // Cytokine. Growth. Factor .Rev. – 2001. – V. 12. – P. 53-72.
198.Nardella, M.I. Oxidation of Human Copper Chaperone Atox1 and Disulfide Bond Cleavage by Cisplatin and Glutathione / M.I. Nardella, A. Rosato, B.D. Belviso et al. // Int. J. Mol. Sci. - 2019. – V. 20 (18). – P. 4390. doi: 10.3390/ijms20184390. PMID: 31500118; PMCID: PMC6769983
199.Nolan, L.P. The value of immunocytochemistry in olistinguishing between clear cell carcinoma of the ovary and kidney / L.P. Nolan, M.K. Heatley // Int. J. Gynecol. Pathol. - 2001. - V. 20 (2). - P. 155159.
200.Paekin, D. Global Cancer Statistics / D. Paekin // CA Cancer. J. Clin. –
1999. – V. 49. – P. 33-64.
201.Poratcal, O. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients / O. Poratcal, O. Ozakaya, M.E. Inal et al. // Clin. Biochem. - 2000. - V. 33 (4). - P. 284-297.
202.Ray, G. Lipid peroxidation, free radical production and antioxidant status in breast cancer / G. Ray, S. Batra, N.K. Shukla et al. // Breast. Cancer. Res. Treat. –
2000. – V. 59 (2). – P. 163-170.
203.Reersi, S. Cytokine changes in Response to Radio-chemotherapeutie Treatment in Head and Neck Cancer / S. Reersi, A. Pfannerstill, D. Rades et al. // Anticancer Research.– 2013. – V. 33. – P. 2481-2490.
204.Rice, C.M. Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression / C.M. Rice, L.C. Davies, J.J. Subleski et al. // Nat. Commun. – 2018. – V. 9(1). – P. 5099.
205.Rohn, W. IL-1 beta inhibits IFN- gamma-induced class II MHC expression by suppressing transcription of the class II transactivator gene / W. Rohn, L.P. Tang, Y. Dong, E.N. Benveniste // J. Immunol. – 1999. – V. 162 (2). – P. 886-896.
206.Rosen, B. Why have ovarian cancer mortality rates declined? Part II: Case-
Рекомендовано к изучению сайтом МедУнивер - https://meduniver.com/
120
fatality / B. Rosen, S.A. Narod // Gynecol. Oncol. – 2015. – V. 138. – P. 750-756.
207.Runnenbaum, I.B. Epidemiological and molecular aspects of ovarian cancer risk / I.B. Runnenbaum, E. Stickeler // J. Cancer. Res. Clin. Oncol. – 2001. – V. 123. – P. 73-79.
208.Rustin, G.J.S. The Gynecologic Oncology Group experience in ovarian cancer / G.J.S. Rustin, A.E. Nelstop, S.M. Bentzen // Annals of Oncology. – 1999. – V. 10. – P. 1-7.
209.Salvador, S. The fallopian tube: primary site of most pelvic high-grade serous carcinomas / S. Salvador, B. Gllks, M. Kobel et al. // Int. J. Gynecol. Cancer. –
2009. – V. 19 (1). – P. 58-64
210.Shacter, Е. Chronic inflammation and cancer / Е. Shacter, S. Weitzman // Oncolojy. – 2002. – V. 16 (2). – P. 217-230.
211.Shih, I.M. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis / I.M. Shih, R.J. Kurman // Am. J. Pathol.
–2004. – V. 164 (5). – P. 1511-1518.
212.Shiels, M.S. Circulating infl ammation markers and prospective risk for lung cancer / M.S. Shiels, R.M. Pfeiffer, A. Hildesheim, E.A. Engels // J. Natl. Cancer. Inst.
–2013. – V. 105 (24). – Р. 1871-1880.
213.Shuchen, L. Interleukin-6 as a prognostic marker for breast cancer: a metaanalysis / L. Shuchen, G. Zhihua // Tumori. – 2015. – V. 10115. – P. 535-541.
214.Siegel, R.L. Cancer statistics 2016 / R.L. Siegel, K.D. Miller, A. Jemal // CA Cancer. J. Clin. – 2016. – V. 66. – P. 7-30.
215.Siegel, R. Cancer Statistics, 2012. / R. Siegel, D. Naishadham, A. Jemal // Ca: Cancer. J. Clin. – 2012. - V. 62. – P. 10-29.
216.Silver, H.J. Changes in body mass, energy balance, physical function, and inflammatory state in patients with locally advanced head and neks cancer treated with concurrent chemoradiation after low-dose induction chemotherapy / H. J. Silver, M.S. Dietrich, D. Murphy // Head Neks. – 2007. – V. 29 (10). – P. 893-900.
217.Skorokhod, O. Doxorubicin pharmacokinetics in lymphoma patients treated with doxorubicin – loaded erythrocytes / O. Skorokhod, E.V. Kulikova, N.M. Yalkina //